Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | PDE6D | O43924 | 1/20 | 0.37 |
| ▸ | PDE6A | P16499 | 1/20 | 0.37 |
| ▸ | PDE6G | P18545 | 1/20 | 0.37 |
| ▸ | PDE6B | P35913 | 1/20 | 0.37 |
| ▸ | PDE6C | P51160 | 1/20 | 0.37 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712420 | 0.87 | KDM4E (0.52) | KDM4EKMT2AHRH4MAPK14AMY1A | |
| SCHEMBL6304236 | 0.82 | HRH4 (0.56) | KDM4EKMT2AHRH4NQO2ALDH1A1 | |
| SCHEMBL3602260 | 0.82 | HRH4 (0.56) | KDM4EKMT2AHRH4NQO2ALDH1A1 | |
| SCHEMBL118875 | 0.81 | KDM4E (0.57) | KDM4EKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL31399981 | 0.81 | KDM4E (0.57) | KDM4EKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL15870617 | 0.81 | KDM4E (0.46) | KDM4EKMT2AMAPK14PDE2APDE10A | |
| SCHEMBL4928778 | 0.81 | NQO2 (0.50) | KDM4EKMT2AHRH4NQO2ALDH1A1 | |
| SCHEMBL804778 | 0.81 | KDM4E (0.46) | KDM4EKMT2AMAPK14PDE2APDE10A | |
| SCHEMBL4928239 | 0.81 | ALDH1A1 (0.59) | KDM4EKMT2AHRH4MAPK14NQO2 | |
| SCHEMBL4931938 | 0.79 | KDM4E (0.44) | KDM4EKMT2AMAPK14NQO2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598173-B2 | 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-12-03 | — | — | US | disclosed |
| EP-2376497-B1 | 5-AMINO-2-(1-HYDROXY-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8314100-B2 | 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2346862-B1 | 2-BENZOTHIOPHENYL-AND 2-NAPHTHYL-0XAZ0LIDIN0NES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| EP-2481735-A1 | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2481735-A1 | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8211890-B2 | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives | Actelion Pharmaceuticals (CH) | 2012-07-03 | — | — | US | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| EP-1819698-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | Rexahn Pharmaceuticals, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006054830-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-4623725-A | [1,2,4]Triazolo[4,3-a]quinoxaline-4-amine derivatives | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0107455-B1 | TRIAZOLOQUINOXALINES AS ANTIDEPRESSANTS AND ANTIFATIGUE AGENTS | PFIZER INC. (US) | 1986-07-09 | — | — | EP | disclosed |
| US-4547501-A | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | PFIZER INC. (US) | 1985-10-15 | — | — | US | disclosed |
| US-4495187-A | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | PFIZER INC. (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0107455-A1 | Triazoloquinoxalines as antidepressants and antifatigue agents | PFIZER INC. (US) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | KDM4E 2103/4885KMT2A 4414/4885HRH4 83/4885 |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | KDM4E 2103/4885KMT2A 4414/4885HRH4 83/4885 |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | HRAS, CDK4, KRAS | KDM4E 843/4885KMT2A 814/4885HRH4 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.